Cytokinetics, Inc. (CYTK) Posts Q2 Loss of 23c/Share
Tweet
Share
E-mailGet Alerts CYTK Hot Sheet
Price: $75.64 --0%
Financial Fact:
Research and development, grant and other revenues: 441K
Today's EPS Names:
VAXX, EGRX, AFIB, More
Financial Fact:
Research and development, grant and other revenues: 441K
Today's EPS Names:
VAXX, EGRX, AFIB, More
Join SI Premium – FREE
Cytokinetics, Inc. (NASDAQ: CYTK) reported Q2 EPS of ($0.23), $0.09 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $7.8 million versus the consensus estimate of $7.01 million.
For earnings history and earnings-related data on Cytokinetics, Inc. (CYTK) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Burry doubles down on Nebius short after stock surges 34% on earnings
- Parker Hannifin completes acquisition of Filtration Group Corporation
- Forum Markets, Incorporated (FRMM) Tops Q2 EPS by 29c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
